Cirqle Biomedical Contraception ApS

Q: What is the CVR number of Cirqle Biomedical Contraception ApS?

Cirqle Biomedical Contraception ApS is registered with CVR / Virk under CVR 39865769.

Q: How many employees does Cirqle Biomedical Contraception ApS have?

Cirqle Biomedical Contraception ApS employs 2 people as of the latest annual report.

Q: Who is the CEO of Cirqle Biomedical Contraception ApS?

Frederik Petursson Madsen is the CEO of Cirqle Biomedical Contraception ApS, in role since 2020.

Q: Who is the chairman of Cirqle Biomedical Contraception ApS?

Jesper Boysen chairs the board of Cirqle Biomedical Contraception ApS, in role since 2020.

Q: Where is Cirqle Biomedical Contraception ApS headquartered?

Cirqle Biomedical Contraception ApS's registered address is Ole Maaløes Vej 3, 3..

APSActiveAdvertising protection

CVR 39865769Ole Maaløes Vej 3, 2200 København NResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2018 · 8 years old2 employees

Overview

Cirqle Biomedical Contraception ApS is a Danish APS based in København N, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2018, the company has 2 employees and reported a gross profit of -DKK 2.4m in its latest annual filing.

Gross profit 2025

-2.4M DKK

−104% vs 2024

EBITDA margin (of gross profit)

261.0 %

−112% vs 2024

Net profit 2025

-6.4M DKK

-115% vs 2024

Key ratios

See full ratios →

93.8 %

Very strong

Among the 20% highest rated companies in the industry

20212025

16.2×

Very strong

Among the 20% highest rated companies in the industry

20212025

-20.4 %

Very weak

Among the 20% lowest rated companies in the industry

20212025

EBITDA — year on year

DKK millions

Key figures

Annual report 2025

Gross profit	-2.4M DKK	-104%
EBITDA	-6.3M DKK	-112%
Net profit	-6.4M DKK	-115%
Total assets	31.5M DKK	-20%
Equity	29.5M DKK	-18%
Employees	2	—

Contact

Address

Ole Maaløes Vej 3, 2200 København N

Phone

+45 2683 1750

fm@cirqle.bio

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), Cirqle Biomedical Contraception ApS reported a gross profit of -DKK 2.4m, a decrease of 104% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of DKK 6.4m.

At the end of 2025, equity financed 93.8% of the balance sheet, and current assets covered short-term debt 16.2 times. Cirqle Biomedical Contraception ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.

Financials

Gross profit

DKK millions

EBITDA

DKK millions

Income statement

DKK thousands

Item	2025	2024	2023	2022	2021
Gross profit	-2,427	60,579	-12,848	62,142	-5,769
Staff expenses	-3,681	-7,273	-8,379	-3,399	-2,729
EBITDA	-6,332	53,153	-21,228	58,743	-8,498
Depreciation & amort.	-25	-55	-8	-0	-0
EBIT	-6,358	53,098	-21,236	58,743	-8,498
Net financials	-829	2,275	448	-375	-283
Profit before tax	-7,187	55,372	-20,788	58,368	-8,781
Tax	-777	11,947	-4,803	10,686	-1,573
Net profit	-6,410	43,425	-15,985	47,682	-7,208

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2025	2024	2023	2022	2021
Total assets	31,468	39,476	45,936	70,219	3,628
Equity	29,521	35,931	34,366	50,351	-4,364
Long-term debt	0	0	8,069	7,477	7,129
Short-term debt	1,947	3,539	3,500	12,391	864
Total debt	1,947	3,539	11,569	19,868	7,992

Financial ratios

5-year trend

EBITDA margin (of gross profit)

<−999 %

20212025

Equity ratio

93.8 %

Very strong

Among the 20% highest rated companies in the industry

20212025

Return on equity

-21.7 %

Very weak

Among the 20% lowest rated companies in the industry

20212025

Net profit margin (of gross profit)

<−999 %

20212025

Asset turnover (of gross profit)

-0.08×

20212025

Debt / equity

0.07×

Very strong

Among the 20% highest rated companies in the industry

20212025

Sector performance

23 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Very weak

Among the 20% lowest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Very weak

Among the 20% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery weak

Among the 10% lowest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Liquidity

Current ratioVery strong

Among the 20% highest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery strong

Among the 20% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery strong

Among the 10% highest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityStrong

Among the 40% highest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalAverage

Around the average of companies in the same industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioWeak

Among the 40% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery strong

Among the 20% highest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery strong

Among the 20% highest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery strong

Among the 20% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery strong

Among the 20% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtVery weak

Among the 10% lowest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery weak

Among the 10% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageWeak

Among the 30% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtVery weak

Among the 10% lowest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery weak

Among the 20% lowest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalVery strong

Among the 10% highest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityWeak

Among the 30% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery strong

Among the 20% highest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (2)
TC Thomas Crouzier Management	Management	2018
FP Frederik Petursson Madsen Chief Executive Officer	Chief Executive Officer	2020

Board of directors

Non-executive oversight

Name	Role	Member since
Current (3)
TC Thomas Crouzier Board of Directors	Board of Directors	2020
FP Frederik Petursson Madsen Board of Directors	Board of Directors	2020
JB Jesper Boysen Chairman	Chairman	2020

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
Cirqle Biomedical Holding ApS	Company	66.67–89.99%	66.67–89.99%	2018
RH CAPITAL FUND II, LP	Individual	5–9.99%	5–9.99%	2022

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

Cirqle Biomedical Holding ApS66.67%

Cirqle Biomedical Contraception ApS (this company)

PharosBio ApS5% owned

Board network connections

Board members of Cirqle Biomedical Contraception ApS also hold positions in 10 other companies.

Person	Role here	Other companies
Jesper Boysen	Chairman	4 companies
Thomas Crouzier	Management	3 companies
Frederik Petursson Madsen	Chief Executive Officer	3 companies

Frequently asked questions

What is the CVR number of Cirqle Biomedical Contraception ApS?

Cirqle Biomedical Contraception ApS is registered with CVR / Virk under CVR 39865769.

What is the gross profit of Cirqle Biomedical Contraception ApS?

Cirqle Biomedical Contraception ApS reported a gross profit of -DKK 2.4m in 2025.

How many employees does Cirqle Biomedical Contraception ApS have?

Cirqle Biomedical Contraception ApS employs 2 people as of the latest annual report.

Who is the CEO of Cirqle Biomedical Contraception ApS?

Frederik Petursson Madsen is the CEO of Cirqle Biomedical Contraception ApS, in role since 2020.

Who is the chairman of Cirqle Biomedical Contraception ApS?

Jesper Boysen chairs the board of Cirqle Biomedical Contraception ApS, in role since 2020.

Where is Cirqle Biomedical Contraception ApS headquartered?

Cirqle Biomedical Contraception ApS's registered address is Ole Maaløes Vej 3, 3..